Pubblicazioni scientifiche sui diagnostici non invasivi BioPredictive

Studi sottoposti a revisione paritaria che convalidano i diagnostici ematici BioPredictive per le malattie del fegato — dalle coorti di sviluppo pionieristiche alle meta-analisi a lungo termine.

159/435 Risultati per
“surrogate markers”

“surrogate markers” Cancella tutto
  1. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases.

    Coco B et al. · J Viral Hepat · 2007 Punteggio 100

    …FibroScan performed better than the other surrogate markers of fibrosis (P < 0…

    FibroTest Alcohol HBV HCV +1

  2. Liver biopsy: the best standard...when everything else fails.

    Poynard T et al. · J Hepatol · 2009 Punteggio 100

    FibroTest Alcohol HBV HCV +1

  3. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.

    Poynard T et al. · Hepatology · 2003 Punteggio 100

    …The aim was to validate their usefulness as surrogate markers of histologic…

    ActiTest FibroTest HCV

  4. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.

    Sberna AL et al. · Diabet Med · 2018 Punteggio 100

    ### Aims To evaluate the application of the recently proposed recommendations by the…

    FibroTest NashTest Metabolic

  5. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

    Zelber-Sagi S et al. · World J Gastroenterol · 2013 Punteggio 99

    …and the SteatoTest, a biochemical surrogate marker of liver steatosis. The FLI…

    SteatoTest Metabolic

  6. Comparison of liver stiffness, fibrotest and liver biopsy for assessment of liver fibrosis in kidney-transplant patients with chronic viral hepatitis.

    Alric L et al. · Transpl Int · 2009 Punteggio 99

    To assess the accuracy of the noninvasive tools, fibrotest (FT) and liver…

    FibroTest HBV HCV

  7. Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy. Key publication

    Anastasiou J et al. · Eur J Gastroenterol Hepatol · 2010 Punteggio 99

    ### Background The efficiency of transient elastography for the assessment of liver fibrosis…

    ActiTest FibroTest Alcohol HBV +3

  8. Noninvasive diagnosis in alcohol-related liver disease.

    Hadefi A et al. · Health Sci Rep · 2020 Punteggio 98

    …Among the noninvasive surrogate markers and techniques used to detect liver fibrosis…

    FibroTest Alcohol

  9. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. Key publication

    Poynard T et al. · J Viral Hepat · 2002 Punteggio 98

    …A fibrosis index combining five biochemical markers (alpha2-macroglobulin, haptoglobin, apolipoprotein A1…

    FibroTest HCV

  10. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Key publication

    Ngo Y et al. · Clin Chem · 2006 Punteggio 98

    ### Background FibroTest, a noninvasive method of measuring biomarkers of liver fibrosis, is…

    FibroTest HCV

  11. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.

    Pais R et al. · Eur J Intern Med · 2015 Punteggio 97

    surrogate for steatosis >5%), IR (HOMA-IR>2.7 as a surrogate

    FibroTest SteatoTest HBV HCV +1

  12. Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B.

    Kim BK et al. · PLoS One · 2012 Punteggio 97

    ### Background And Aims Diagnostic values of FibroTest (FT) for hepatic fibrosis have…

    FibroTest HBV

  13. Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?

    Poynard T et al. · Gastroenterology · 2005 Punteggio 97

    ActiTest FibroTest Alcohol HBV +3

  14. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. Key publication

    Poynard T et al. · J Viral Hepat · 2009 Punteggio 96

    …ActiTest (FT-AT) as noninvasive markers of histological changes in patients with…

    ActiTest FibroTest HBV

  15. The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C.

    Le Calvez S et al. · Hepatology · 2004 Punteggio 96

    FibroTest HCV

  16. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.

    Ratziu V et al. · J Hepatol · 2011 Punteggio 96

    …HD-UDCA also significantly improved markers of glycemic control and insulin resistance…

    FibroTest Metabolic

  17. Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis.

    Haseltine EL et al. · J Viral Hepat · 2015 Punteggio 95

    …However, not all correlations observed between noninvasive markers and fibrosis stage at…

    FibroTest HCV

  18. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. Key publication

    Ngo Y et al. · PLoS One · 2008 Punteggio 95

    ### Background The combination of transaminases (ALT), biopsy, HBeAg and viral load have…

    ActiTest FibroTest HCV

  19. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?

    Thabut D et al. · Am J Gastroenterol · 2006 Punteggio 95

    …Biochemical markers seem particularly useful as a noninvasive alternative to liver biopsy…

    FibroTest HCV

  20. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.

    European Association for the Study of the Liver (EASL) et al. · Obes Facts · 2016 Punteggio 95

    FibroTest SteatoTest Metabolic

  21. Discordance between liver biopsy and FibroTest in assessing liver fibrosis in chronic hepatitis B.

    Park MS et al. · PLoS One · 2013 Punteggio 94

    ### Background And Aims The FibroTest (FT) demonstrated excellent diagnostic performance in the…

    FibroTest HBV

  22. Liver fibrosis in young Egyptian beta-thalassemia major patients: relation to hepatitis C virus and compliance with chelation.

    Elalfy MS et al. · Ann Hepatol · 2013 Punteggio 94

    ### Background The main causes of liver fibrosis in transfusion-dependent thalassemia major…

    ActiTest FibroTest HCV

  23. Is it possible to predict HCV-related liver cirrhosis non-invasively through routine laboratory parameters? Review

    Gentile I et al. · Infez Med · 2014 Punteggio 94

    It is estimated that hepatitis C virus (HCV) infects chronically about 160…

    FibroTest HCV

  24. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

    Castéra L et al. · Gastroenterology · 2005 Punteggio 93

    …combined with currently available biochemical markers (Fibrotest; Biopredictive; and the aspartate transaminase…

    FibroTest HCV

  25. Liver stiffness measurement and biochemical markers in Senegalese chronic hepatitis B patients with normal ALT and high viral load.

    Mbaye PS et al. · PLoS One · 2011 Punteggio 93

    …LSM and liver fibrosis biochemical markers were performed on 225 consecutive HBV…

    FibroTest HBV

  26. Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B.

    Kim BK et al. · PLoS One · 2012 Punteggio 93

    ### Background And Aims Liver stiffness measurement (LSM) and FibroTest (FT) are frequently…

    FibroTest HBV

  27. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.

    Poynard T et al. · J Hepatol · 2012 Punteggio 92

    ### Background & Aims Time-dependent statistics have been used to assess liver fibrosis…

    FibroTest Alcohol HBV HCV +1

  28. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication Meta Analysis

    Halfon P et al. · Gastroenterol Clin Biol · 2008 Punteggio 92

    FibroTest (FT) is a biomarker of liver fibrosis initially validated in patients…

    FibroTest Alcohol HBV HCV +2

  29. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.

    Poynard T et al. · J Hepatol · 2013 Punteggio 92

    ### Background & Aims Chronic hepatitis C is both a virologic and fibrotic disease…

    FibroTest HCV

  30. Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus.

    Varaut A et al. · Transplantation · 2005 Punteggio 91

    ### Background An accurate diagnosis of hepatitis C virus (HCV)-related liver lesions…

    FibroTest HCV

  31. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. Review

    Castera L · J Viral Hepat · 2009 Punteggio 91

    …using transient elastography, and serum markers, ranging from routine laboratory tests to…

    FibroTest HBV HCV HIV

  32. The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease. Key publication

    Thabut D et al. · J Hepatol · 2006 Punteggio 91

    ### Background/Aims The aim was to identify a panel of biomarkers (AshTest…

    AshTest Alcohol

  33. Noninvasive prediction of fibrosis in patients with chronic hepatitis C.

    Thabut D et al. · Hepatology · 2003 Punteggio 90

    FibroTest HCV

  34. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.

    Perazzo H et al. · Aliment Pharmacol Ther · 2014 Punteggio 90

    ### Background In cardiometabolic disorders, non-alcoholic fatty liver disease is frequent and…

    FibroTest SteatoTest Metabolic

  35. Hepatitis B: are non-invasive markers of liver fibrosis reliable? Review

    Castera L · Liver Int · 2014 Punteggio 90

    Liver biopsy, which was traditionally considered to be the gold standard for…

    FibroTest HBV HCV

  36. Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®).

    Poynard T et al. · J Hepatol · 2014 Punteggio 89

    …been validated as non-invasive markers of METAVIR fibrosis stages from F0…

    FibroTest HCV

  37. Effective use of FibroTest to generate decision trees in hepatitis C.

    Lau-Corona D et al. · World J Gastroenterol · 2009 Punteggio 89

    ### Aim To assess the usefulness of FibroTest to forecast scores by constructing…

    FibroTest HCV

  38. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection.

    Poynard T et al. · Am J Gastroenterol · 2005 Punteggio 89

    ### Objectives The noninvasive serum markers, FibroTest-ActiTest (FT-AT), are an alternative…

    ActiTest FibroTest HBV

  39. Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. Key publication

    Poynard T et al. · PLoS One · 2020 Punteggio 89

    ### Background Since 1920, a decrease in serum cholesterol has been identified as…

    FibroTest Other

  40. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Key publication

    Poynard T et al. · Clin Chem · 2004 Punteggio 88

    ### Background The FibroTest and ActiTest are noninvasive biochemical markers of liver injury…

    ActiTest FibroTest HCV

  41. Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?

    Bush AM et al. · Aliment Pharmacol Ther · 2018 Punteggio 88

    FibroTest Metabolic

  42. Non-invasive evaluation of liver fibrosis by transient elastography and biochemical markers in elderly inpatients.

    Salles N et al. · Gastroenterol Clin Biol · 2009 Punteggio 88

    …transient elastography (FibroScan) and biochemical markers (Hepascore, Aspartate Transaminase (AST) to platelet…

    FibroTest Metabolic

  43. Appropriate evidence-based data overviews demonstrate the diagnostic and prognostic performances of FibroTest in patients with chronic hepatitis C.

    Poynard T et al. · Aliment Pharmacol Ther · 2009 Punteggio 87

    FibroTest HCV

  44. ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure. Meta Analysis

    Poynard T et al. · Gastroenterol Clin Biol · 2010 Punteggio 87

    ### Background ActiTest (AT) is a biomarker of liver necro-inflammatory histological activity…

    ActiTest HCV

  45. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication

    European Association for Study of Liver et al. · J Hepatol · 2015 Punteggio 87

    FibroTest Alcohol HBV HCV +3

  46. Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C.

    Lewin M et al. · Hepatology · 2007 Punteggio 86

    ### Unlabelled Liver biopsy is the gold standard for assessing fibrosis but has…

    FibroTest HCV

  47. An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.

    Patel K et al. · J Viral Hepat · 2009 Punteggio 86

    Noninvasive markers that accurately follow changes in fibrosis may provide alternatives to…

    FibroTest HCV

  48. Biomarkers of liver fibrosis. Review

    Poynard T et al. · Adv Clin Chem · 2008 Punteggio 86

    Liver biopsy, due to its limitations and risks, is an imperfect gold…

    ActiTest FibroTest SteatoTest Alcohol +5

  49. Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.

    Copaci I et al. · Rom J Intern Med · 2015 Punteggio 85

    ### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance…

    SteatoTest Metabolic

  50. Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B.

    Poynard T et al. · Curr Hepat Rep · 2011 Punteggio 85

    A serum biomarker (FibroTest; Biopredictive, Paris, France; FibroSure; LabCorp, Burlington, USA) and…

    FibroTest HBV

  51. Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods. Review

    Festi D et al. · Aliment Pharmacol Ther · 2013 Punteggio 85

    ### Background Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of…

    SteatoTest

  52. Impact of steatosis and inflammation definitions on the performance of NASH tests.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Punteggio 84

    ### Background And Aim One of the unmet needs in subjects with metabolic…

    ActiTest FibroTest NashTest NashTest-2 +3

  53. Progression of liver fibrosis among injection drug users with chronic hepatitis C.

    Wilson LE et al. · Hepatology · 2006 Punteggio 84

    …Predictive values of blood markers [FibroSURE, aspartate aminotransferase-to-platelet-ratio index…

    FibroTest

  54. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia.

    Ratziu V et al. · Aliment Pharmacol Ther · 2007 Punteggio 84

    ### Background Mortality related to complications of cirrhosis is increasing in patients with…

    FibroTest NashTest SteatoTest Metabolic

  55. Diagnostic value of FibroTest with normal serum aminotransferases.

    Poynard T et al. · Hepatology · 2006 Punteggio 84

    FibroTest HCV

  56. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Review

    Ahmad W et al. · Virol J · 2011 Punteggio 83

    …We examined year wise results of these markers based on their sensitivity…

    FibroTest HCV

  57. Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).

    Poynard T et al. · J Hepatol · 2014 Punteggio 83

    …and transient elastography (TE) as markers of occurrence of cirrhosis without complications…

    ActiTest FibroTest HBV

  58. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Punteggio 83

    ### Background One of the unmet needs in patients with metabolic risks is…

    FibroTest NashTest SteatoTest Metabolic

  59. Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study.

    Poynard T et al. · J Hepatol · 2013 Punteggio 82

    ### Background & Aims Therapeutic options for patients failing hepatitis C retreatment are limited…

    ActiTest FibroTest HBV

  60. FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program.

    Poynard T et al. · J Hepatol · 2011 Punteggio 82

    ### Background & Aims EPIC-3 is a prospective, international study that has demonstrated…

    FibroTest HCV

  61. Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients.

    Beckebaum S et al. · Transplantation · 2010 Punteggio 82

    ### Background This prospective, monocentric study was designed to assess the efficacy of…

    FibroTest Alcohol HBV HCV +2

  62. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Meta Analysis

    Shaheen AA et al. · Am J Gastroenterol · 2007 Punteggio 81

    ### Background The accurate diagnosis of hepatitis C virus (HCV)-related fibrosis is…

    FibroTest Alcohol HBV HCV

  63. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors.

    Imbert-Bismut F et al. · Clin Chem Lab Med · 2004 Punteggio 81

    Combinations of tests comprising alpha2-macroglobulin, haptoglobin, apolipoprotein Al, gamma-glutamyltransferase, total…

    ActiTest FibroTest HCV

  64. Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Key publication

    Shiha G et al. · Hepatol Int · 2009 Punteggio 81

    Liver fibrosis is a common pathway leading to cirrhosis, which is the…

    FibroTest SteatoTest HBV HCV +1

  65. Assessment of liver fibrosis: noninvasive means.

    Poynard T et al. · Saudi J Gastroenterol · 2008 Punteggio 80

    Liver biopsy, owing to its limitations and risks, is an imperfect gold…

    FibroTest Alcohol HBV HCV +3

  66. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.

    Vergniol J et al. · Gastroenterology · 2011 Punteggio 80

    ### Background & Aims Liver stiffness can be measured noninvasively to assess liver fibrosis…

    FibroTest HCV HIV

  67. Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies. Meta Analysis

    Poynard T et al. · Antivir Ther · 2010 Punteggio 80

    ### Background Liver biopsy and virological end points are standard references for assessing…

    ActiTest FibroTest HBV HCV +1

  68. Fibrotest-Actitest: the biochemical marker of liver fibrosis--the Israeli experience.

    Morali G et al. · Isr Med Assoc J · 2007 Punteggio 79

    ### Background The Fibrotest-Actitest is a six-parameter scoring system that allows…

    ActiTest FibroTest Alcohol HBV +1

  69. [SWE elastography in assessment of liver fibrosis]. Review

    Zaleska-Dorobisz U et al. · Postepy Hig Med Dosw (Online) · 2015 Punteggio 79

    Liver fibrosis is a relatively common consequence of chronic liver diseases, especially…

    FibroTest HBV HCV

  70. Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study.

    Boyd A et al. · J Int AIDS Soc · 2017 Punteggio 79

    ### Introduction Long-term tenofovir disoproxil fumarate (TDF) use has been associated with…

    FibroTest HBV HIV

  71. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Review

    Moreno C et al. · J Hepatol · 2019 Punteggio 78

    Even though alcohol-related liver disease (ALD) is a major cause of…

    FibroTest Alcohol

  72. Noninvasive evaluation of NAFLD. Review

    Castera L et al. · Nat Rev Gastroenterol Hepatol · 2013 Punteggio 78

    …Of the noninvasive serum markers, the NAFLD fibrosis score is the most…

    ActiTest FibroTest NashTest SteatoTest +1

  73. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients.

    Myers RP et al. · AIDS · 2003 Punteggio 78

    …non-invasive index of biochemical markers for the prediction of fibrosis in…

    FibroTest HCV HIV

  74. Comparison of FibroTest-ActiTest with histopathology in demonstrating fibrosis and necroinflammatory activity in chronic hepatitis B and C.

    Uyar C et al. · Indian J Pathol Microbiol · 2010 Punteggio 78

    …both determined via serum biochemical markers, were compared with levels of fibrosis…

    ActiTest FibroTest HBV HCV

  75. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication Review

    Munteanu M et al. · J Gastrointestin Liver Dis · 2008 Punteggio 77

    ActiTest AshTest FibroTest NashTest +6

  76. Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review

    Bril F et al. · Diabetes Care · 2017 Punteggio 77

    Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently…

    FibroTest Metabolic

  77. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.

    Chou R et al. · Ann Intern Med · 2013 Punteggio 77

    ### Background Many blood tests have been proposed as alternatives to liver biopsy…

    FibroTest HCV

  78. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Comp Hepatol · 2005 Punteggio 76

    …significantly higher than the standard markers: gamma-glutamyl-transpeptidase or alanine aminotransferase…

    SteatoTest Alcohol HBV HCV +1

  79. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest.

    Vallet-Pichard A et al. · Hepatology · 2007 Punteggio 76

    ### Unlabelled To optimize the management of patients with chronic hepatitis C virus…

    FibroTest HCV

  80. Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C.

    Khalaf N et al. · Clin Gastroenterol Hepatol · 2015 Punteggio 76

    ### Background & Aims Coffee or caffeine has been proposed to protect against hepatic…

    FibroTest HCV

  81. Correlation between liver biopsy and fibrotest in the evaluation of hepatic fibrosis in patients with chronic hepatitis C.

    Said Y et al. · Tunis Med · 2010 Punteggio 75

    ### Aim To assess the diagnostic value of Fibrotest in comparison with liver…

    FibroTest HCV

  82. Non-invasive markers for hepatic fibrosis. Review

    Baranova A et al. · BMC Gastroenterol · 2011 Punteggio 75

    With great advancements in the therapeutic modalities used for the treatment of…

    FibroTest Alcohol HBV HCV +3

  83. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease.

    Halfon P et al. · Comp Hepatol · 2002 Punteggio 75

    …Biochemical markers for liver fibrosis (FibroTest) and necroinflammatory features (ActiTest) are an…

    ActiTest FibroTest Alcohol HCV

  84. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?

    Poynard T et al. · Expert Rev Mol Diagn · 2005 Punteggio 74

    …combinations of simple serum biochemical markers in patients infected with hepatitis B…

    ActiTest FibroTest Alcohol HBV +2

  85. Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection. Meta Analysis

    Shaheen AA et al. · HIV Clin Trials · 2008 Punteggio 74

    ### Background Accurately staging hepatitis C virus (HCV)-related fibrosis is crucial for…

    FibroTest HCV HIV

  86. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study.

    Laharie D et al. · J Hepatol · 2010 Punteggio 74

    …In a multivariate analysis, factors associated with abnormal markers of liver fibrosis…

    FibroTest Other

  87. Concordance of non-invasive serology-based scoring indices and transient elastography for liver fibrosis and cirrhosis in chronic hepatitis C.

    Trnačević E et al. · Med Glas (Zenica) · 2021 Punteggio 73

    …AUROC), the best performing serum markers for significant liver fibrosis (METAVIR ≥F2…

    FibroTest HCV

  88. Noninvasive Assessment of Liver Fibrosis.

    Castera L · Dig Dis · 2015 Punteggio 73

    ### Background The prognosis and management of chronic liver diseases greatly depend on…

    FibroTest HBV HCV

  89. Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C.

    Shlomai A et al. · J Viral Hepat · 2013 Punteggio 73

    Serum bile acids (SBAs) are commonly elevated in cholestatic liver diseases, but…

    FibroTest HCV

  90. Noninvasive Testing for Nonalcoholic Steatohepatitis and Hepatic Fibrosis in Patients With Psoriasis Receiving Long-term Methotrexate Sodium Therapy.

    Bauer B et al. · JAMA Dermatol · 2017 Punteggio 73

    ### Importance The long-term implications of hepatotoxic effects in patients with psoriasis…

    FibroTest NashTest Other

  91. Non-invasive Investigations for the Diagnosis of Fontan-Associated Liver Disease in Pediatric and Adult Fontan Patients.

    Fidai A et al. · Front Cardiovasc Med · 2017 Punteggio 72

    …However, diagnostic markers for this condition are limited. We hypothesized that specific…

    FibroTest Other

  92. Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases.

    Sebastiani G et al. · J Viral Hepat · 2008 Punteggio 72

    …Few studies investigated noninvasive markers of liver fibrosis in hepatitis C virus…

    FibroTest HCV

  93. Role of Non-hepatic Medical Comorbidity and Functional Limitations in Predicting Mortality in Patients with HCV.

    Natarajan Y et al. · Dig Dis Sci · 2017 Punteggio 72

    ### Background Medical comorbidities and functional status limitations are determinants of mortality in…

    FibroTest HCV

  94. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis.

    Berends MA et al. · Liver Int · 2007 Punteggio 71

    ### Background Methotrexate (MTX) use is associated with hepatic fibrosis in psoriasis patients…

    FibroTest Other

  95. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C.

    Sebastiani G et al. · Hepatology · 2009 Punteggio 71

    …not adequately classifiable by noninvasive markers. Hepatitis C virus (HCV) patients (2035…

    FibroTest HCV

  96. Prognostic value of the combined use of transient elastography and fibrotest in patients with chronic hepatitis B.

    Park MS et al. · Liver Int · 2015 Punteggio 71

    ### Background & Aims Liver stiffness (LS) measurement using transient elastography and the FibroTest…

    FibroTest HBV

  97. Prognostic value of liver fibrosis biomarkers: a meta-analysis.

    Poynard T et al. · Gastroenterol Hepatol (N Y) · 2011 Punteggio 70

    ### Aims And Methods Several serum biomarkers such as FibroTest, aspartate transaminase-platelet…

    FibroTest Alcohol HBV HCV +3

  98. Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients.

    Maor Y et al. · Haemophilia · 2007 Punteggio 70

    Non-invasive biomarkers have gained popularity for estimating fibrosis stage. In our…

    FibroTest HCV

  99. Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy.

    de Lédinghen V et al. · J Pediatr Gastroenterol Nutr · 2007 Punteggio 70

    ### Objective Transient elastography (FibroScan) is a novel, noninvasive, rapid bedside method to…

    FibroTest HBV HCV Other

  100. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Key publication

    Poynard T et al. · Clin Chem · 2007 Punteggio 69

    …the diagnostic value for fibrosis markers. Whether there is variability in the…

    FibroTest HCV

  101. Changes of non-invasive markers and FibroScan values during HCV treatment.

    Vergniol J et al. · J Viral Hepat · 2009 Punteggio 69

    The recent advent of non-invasive methods for assessment of fibrosis allows…

    FibroTest HCV

  102. Applicability and variability of liver stiffness measurements according to probe position.

    Ingiliz P et al. · World J Gastroenterol · 2009 Punteggio 69

    ### Aim To investigate the liver stiffness measurement (LSM) applicability and variability with…

    FibroTest Alcohol HBV HCV +3

  103. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease.

    Naveau S et al. · Clin Gastroenterol Hepatol · 2005 Punteggio 68

    …the diagnostic use of noninvasive markers of fibrosis in patients with chronic…

    FibroTest Alcohol

  104. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C.

    Castéra L et al. · J Hepatol · 2010 Punteggio 68

    ### Background & Aims Non-invasive assessment of liver fibrosis is a challenging area…

    FibroTest HCV

  105. HCV-GenoFibrotest: a combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C.

    Costa JM et al. · Clin Res Hepatol Gastroenterol · 2011 Punteggio 68

    ### Background And Aim Three gene polymorphisms, interferon-lambda-3 (IL28B), inosinetriphosphatase (ITPA…

    ActiTest FibroTest HCV-GenoFibroTest SteatoTest +1

  106. Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers.

    Friedrich-Rust M et al. · J Thorac Cardiovasc Surg · 2008 Punteggio 67

    …to the measured biochemical fibrosis markers. The Spearman correlation coefficient between the…

    ActiTest FibroTest Other

  107. Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest).

    Munteanu M et al. · Comp Hepatol · 2004 Punteggio 67

    …The intra-individual variation of biochemical markers was low, and it was…

    ActiTest FibroTest Alcohol HBV +3

  108. Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis.

    Sène D et al. · Clin Biochem · 2006 Punteggio 67

    ### Objective And Methods We assessed the reliability of non-invasive biological scoring…

    ActiTest FibroTest HCV

  109. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B.

    Sebastiani G et al. · World J Gastroenterol · 2007 Punteggio 67

    ### Aim To assess the performance of several non-invasive markers and of…

    FibroTest HBV

  110. Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".

    Perazzo H et al. · Clin Res Hepatol Gastroenterol · 2014 Punteggio 66

    ### Background The aspartate aminotransferase platelet ratio index (APRI) is a validated, non…

    FibroTest Alcohol HBV HCV +1

  111. Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up.

    Calin R et al. · J Clin Virol · 2013 Punteggio 66

    ### Background Due to common routes of transmission, HIV and HBV are frequently…

    FibroTest HBV HIV

  112. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B.

    Myers RP et al. · J Hepatol · 2003 Punteggio 66

    …The aim was to determine the diagnostic utility of noninvasive serum markers

    ActiTest FibroTest HBV

  113. Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers.

    Poynard T et al. · PLoS One · 2008 Punteggio 65

    ### Background Assessing liver fibrosis is traditionally performed by biopsy, an imperfect gold…

    FibroTest Alcohol HBV HCV +3

  114. A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers.

    d'Arondel C et al. · J Viral Hepat · 2006 Punteggio 65

    …a significant decrease in fibrosis and activity as estimated by biochemical markers.

    ActiTest FibroTest HCV

  115. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive.

    Boursier J et al. · Hepatology · 2012 Punteggio 65

    ### Unlabelled The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm…

    FibroTest HCV

  116. FibroMAX: towards a new universal biomarker of liver disease? Review

    Morra R et al. · Expert Rev Mol Diagn · 2007 Punteggio 64

    …combinations of simple serum biochemical markers (the super combination being FibroMAX (BioPredictive…

    ActiTest AshTest FibroTest NashTest +7

  117. Molecular characteristics of Hepatitis B and chronic liver disease in a cohort of HB carriers from Bamako, Mali.

    Traoré F et al. · BMC Infect Dis · 2015 Punteggio 64

    ### Background Hepatitis B (HB) infection is common in Mali. However, there is…

    ActiTest FibroTest HBV

  118. Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea.

    Minville C et al. · Chest · 2014 Punteggio 64

    ### Background Nocturnal hypoxia, the hallmark of OSA, is a potential contributing factor…

    FibroTest NashTest SteatoTest Metabolic

  119. The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis.

    Lynch M et al. · JAMA Dermatol · 2014 Punteggio 63

    ### Importance There is a need for noninvasive tools to monitor hepatotoxicity in…

    FibroTest Other

  120. Impact of quality control accepted inter-laboratory variations on calculated Fibrotest/Actitest scores for the non-invasive biochemical assessment of liver fibrosis.

    Gressner OA et al. · Clin Chim Acta · 2009 Punteggio 63

    ### Introduction Non-invasive, i.e. serum-based assessment of liver fibrosis is…

    ActiTest FibroTest HCV

  121. Prospective noninvasive analysis of hepatic fibrosis in patients with Crohn's disease: correlation of transient elastography and laboratory-based markers.

    Brühl J et al. · Eur J Gastroenterol Hepatol · 2011 Punteggio 63

    …This study aimed to prospectively assess the potential of noninvasive markers for…

    FibroTest Other

  122. Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.

    Akuta N et al. · J Gastroenterol · 2018 Punteggio 62

    ### Background In the UNITY-3 study, 96% sustained virologic response (SVR12) rate…

    FibroTest HCV

  123. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study.

    Zarski JP et al. · J Hepatol · 2012 Punteggio 62

    ### Background & Aims Blood tests and transient elastography (Fibroscan™) have been developed as…

    FibroTest HCV

  124. Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.

    Giannini EG et al. · J Gastroenterol Hepatol · 2015 Punteggio 62

    ### Background And Aim Thrombocytopenia is frequently observed in patients with chronic hepatitis…

    FibroTest HCV

  125. Liver fibrosis: noninvasive assessment with acoustic radiation force impulse elastography--comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease.

    Cassinotto C et al. · Radiology · 2013 Punteggio 62

    ### Purpose To compare the diagnostic performance of acoustic radiation force impulse (ARFI…

    FibroTest Alcohol HBV HCV +2

  126. Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers.

    Castéra L et al. · Aliment Pharmacol Ther · 2011 Punteggio 61

    ### Background Non invasive methods for fibrosis evaluation remain to be validated longitudinally…

    FibroTest HBV

  127. Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard.

    Poynard T et al. · J Hepatol · 2012 Punteggio 61

    ### Background & Aims Liver fibrosis stage is traditionally assessed with biopsy, an imperfect…

    FibroTest HCV

  128. Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.

    Meritsi A et al. · Clin Diabetes · 2022 Punteggio 61

    Nonalcoholic fatty liver disease (NAFLD) is dramatically increasing in parallel with the…

    ActiTest FibroTest NashTest-2 Metabolic

  129. Optimization and robustness of blood tests for liver fibrosis and cirrhosis.

    Calès P et al. · Clin Biochem · 2010 Punteggio 60

    …or blood markers. ### Results The bootstrap method validated the markers of the…

    FibroTest HCV

  130. Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C.

    Morra R et al. · Aliment Pharmacol Ther · 2007 Punteggio 60

    ### Background FibroTest has been validated for the diagnosis of liver fibrosis in…

    FibroTest Alcohol HBV HCV +1

  131. Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.

    Rudler M et al. · PLoS One · 2015 Punteggio 60

    ### Background/Aims According to guidelines, the histological diagnosis of severe alcoholic steatohepatitis…

    AshTest Alcohol

  132. FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate.

    Poynard T et al. · Clin Res Hepatol Gastroenterol · 2011 Punteggio 59

    ### Background Two widely used biomarkers of fibrosis, FibroTest and liver stiffness measurement…

    FibroTest HCV

  133. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.

    Poynard T et al. · Lancet · 1997 Punteggio 59

    ### Background Our aim was to assess the natural history of liver fibrosis…

    HCV

  134. Hepatic and renal end-organ damage in the Fontan circulation: A report from the Australian and New Zealand Fontan Registry.

    Wilson TG et al. · Int J Cardiol · 2018 Punteggio 59

    ### Background Hepatic and renal dysfunction have been observed in survivors of the…

    FibroTest Other

  135. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection

    · 2015 Punteggio 58

    These are the first World Health Organization (WHO) guidelines for the prevention…

    FibroTest HBV

  136. Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.

    Sebastiani G et al. · Can J Gastroenterol Hepatol · 2014 Punteggio 58

    ### Objective To determine practices among physicians in Canada for the assessment of…

    FibroTest Alcohol HBV HCV +3

  137. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study).

    Degos F et al. · J Hepatol · 2010 Punteggio 58

    ### Background & Aims The diagnostic accuracy of non-invasive liver fibrosis tests that…

    FibroTest HBV HCV HIV

  138. Childhood/adult-onset lysosomal acid lipase deficiency: A serious metabolic and vascular phenotype beyond liver disease-four new pediatric cases.

    Poinsot P et al. · J Clin Lipidol · 2017 Punteggio 57

    ### Background The childhood/adult-onset lysosomal acid lipase deficiency (LALD; late-onset…

    FibroTest Metabolic

  139. Personalized management of cirrhosis by non-invasive tests of liver fibrosis. Review

    Wong GL et al. · Clin Mol Hepatol · 2015 Punteggio 57

    Owing to the high prevalence of various chronic liver diseases, cirrhosis is…

    FibroTest Alcohol HBV HCV +1

  140. Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease. Review

    Lombardi R et al. · World J Gastroenterol · 2015 Punteggio 57

    …Currently, although several non-invasive fibrosis markers have been suggested as alternatives…

    FibroTest Alcohol

  141. FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus.

    Patel K et al. · World J Gastroenterol · 2011 Punteggio 56

    ### Aim To compare histological endpoint assessment using noninvasive alternatives to biopsy during…

    FibroTest HCV

  142. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.

    Stevenson M et al. · Health Technol Assess · 2012 Punteggio 56

    ### Background Excessive alcohol consumption may lead to the development of alcohol-related…

    FibroTest Alcohol

  143. Meta-analyses of FibroTest diagnostic value in chronic liver disease. Key publication Meta Analysis

    Poynard T et al. · BMC Gastroenterol · 2007 Punteggio 56

    ### Background FibroTest (FT) is a biomarker of liver fibrosis initially validated in…

    FibroTest Alcohol HBV HCV +1

  144. Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV. Review

    Matta B et al. · Curr HIV/AIDS Rep · 2016 Punteggio 56

    …on direct and/or indirect markers) such as APRI, FIB4, FibroTest, FibroSpect…

    FibroTest HBV HCV HIV

  145. EASL clinical practical guidelines: management of alcoholic liver disease.

    European Association for the Study of Liver · J Hepatol · 2012 Punteggio 55

    FibroTest Alcohol

  146. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C.

    Poynard T et al. · Comp Hepatol · 2004 Punteggio 55

    …In 2001, FibroTest ActiTest (FT-AT), a panel of biochemical markers, was…

    ActiTest FibroTest HCV

  147. Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.

    Poynard T et al. · BMJ Open · 2015 Punteggio 55

    ### Background Effective antiviral treatment (direct-acting antiviral agents (DAAs)), the requirement for…

    ActiTest FibroTest Alcohol HBV +3

  148. The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2019 Punteggio 54

    ### Background Serum biomarkers of steatosis such as the SteatoTest are recommended for…

    NashTest-2 SteatoTest-2 Metabolic

  149. Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication Review

    Poynard T et al. · Gastroenterol Clin Biol · 2008 Punteggio 54

    This review summarizes the methodological aspects of the interpretation of non-invasive…

    ActiTest FibroTest SteatoTest Alcohol +5

  150. Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C.

    Chen SH et al. · BMC Gastroenterol · 2012 Punteggio 54

    ### Background Previous research has shown variation in the effects of patient factors…

    FibroTest HCV

  151. Biomarkers for liver disease in urea cycle disorders.

    Nagamani SCS et al. · Mol Genet Metab · 2021 Punteggio 53

    ### Background Urea cycle disorders (UCDs) are among the most common inborn errors…

    ActiTest FibroTest Other

  152. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication

    Ratziu V et al. · BMC Gastroenterol · 2006 Punteggio 53

    …diagnostic utility of non-invasive markers of fibrosis, validated in chronic viral…

    FibroTest Metabolic

  153. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication

    Poynard T et al. · BMC Gastroenterol · 2006 Punteggio 53

    ### Background Liver biopsy is considered the gold standard for assessing histologic lesions…

    NashTest Metabolic

  154. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. Review

    Parikh P et al. · Ann Transl Med · 2017 Punteggio 52

    Chronic hepatitis B virus (HBV) infection is a major cause of liver…

    FibroTest HBV

  155. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis. Meta Analysis

    Salkic NN et al. · Am J Gastroenterol · 2014 Punteggio 52

    ### Objectives Extent of liver fibrosis is one of the most important factors…

    FibroTest HBV

  156. Non-invasive diagnosis of hepatitis B virus-related cirrhosis. Review

    Lee S et al. · World J Gastroenterol · 2014 Punteggio 52

    Chronic hepatitis B (CHB) infection is a major public health problem associated…

    FibroTest HBV

  157. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication

    Myers RP et al. · Can J Gastroenterol · 2012 Punteggio 51

    Chronic hepatitis C remains a significant medical and economic burden in Canada…

    FibroTest HCV

  158. Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. Key publication

    Deckmyn O et al. · Biomedicines · 2022 Punteggio 51

    In patients with non-alcoholic fatty liver disease (NAFLD) with or without…

    FibroTest Metabolic

  159. Prise en charge des personnes infectées par les virus de l’hépatite B ou de l’hépatite C — Rapport de recommandations 2014 Key publication

    Punteggio 51

    FibroTest HBV HCV

Mostra l'elenco completo dei risultati. La pagina è renderizzata sul server e non è paginata.